Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
Amphastar Pharmaceuticals (AMPH) Stock Price & Analysis
313 Followers
AMPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.43 - $67.66
Previous Close$42.21
Volume595.85K
Average Volume (3M)415.73K
Market Cap
$2.06B
Enterprise Value$2.43B
Total Cash (Recent Filing)$256.81M
Total Debt (Recent Filing)$623.64M
Price to Earnings (P/E)14.5
Beta0.63
Next Earnings
Aug 05, 2024EPS Estimate
$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.90
Shares Outstanding48,095,862
10 Day Avg. Volume370,929
30 Day Avg. Volume415,726
Standard Deviation0.12
R-Squared0.15
Alpha0.00835
Financial Highlights & Ratios
Price to Book (P/B)78.11
Price to Sales (P/S)3.15
Price to Cash Flow (P/CF)21.40
P/FCF Ratio22.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.25
Enterprise Value/Gross Profit6.92
Enterprise Value/Ebitda9.69
Forecast
1Y Price Target
$62.60Price Target Upside48.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Amphastar Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAmphastar's financials show a robust performance with a significant beat on the bottom line driven by lower operating expenses and a positive adjustment in net income.
Market PositionAmphastar benefits from a strong market position as the sole provider of epinephrine in pre-filled syringes for hospitals, highlighting its unique offering in critical care.
Product AdvantageBaqsimi stands out in the glucagon market with a patent protection until 2036 and a unique nasal administration method, distinguishing it from competitors.
Bears Say
Financial PerformanceAmphastar’s 1Q update included a modest revenue miss.
Product PerformanceProducts like Glucagon, Primatene Mist and hospital products are not growing at levels of prior years.
Regulatory ChallengesAlthough teriparatide received a CRL, AMPH plans to respond and expects an FDA action date.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AMPH FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was $38.43 and its highest was $67.66 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Aug 05, 2024 which is in 86 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on May 08, 2024. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.773 by $0.267.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is $0.8.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,865,936 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of $1.04 in its last earnings report, beating expectations of $0.773. Following the earnings report the stock price went up 0.521%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Amphastar Pharmaceuticals’s shares valued at 701K.
---
Amphastar Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$62.60 (48.31% Upside)
$62.60 (48.31% Upside)
Blogger Sentiment
Bullish
AMPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 13.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $589.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.47%
12-Months-Change
Fundamentals
Return on Equity
25.34%
Trailing 12-Months
Asset Growth
103.49%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
AMPH Company Deck
---
AMPH Earnings Call
Q1 2024
0:00 / 0:00
---
AMPH Stock 12 Month Forecast
Average Price Target
$62.60
▲(48.31% Upside)
Technical Analysis
Best Analysts Covering AMPH
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+27.23%
reiterated a buy rating 3 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +27.23% per trade.
---